Reva Medical presented four key data sets demonstrating the capabilities of the company’s Fantom bioresorbable scaffold (BRS) at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference.
Visit WebsiteWhile both blunt and bold, it resonated with me as it accurately summarized the cardiovascular information and imaging systems (CVIS) market, as well as my own experience with various CVIS deployments.
Visit WebsiteA high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and moderate cases of prosthesis-patient mismatch (PPM), meaning the implanted heart valve is too small for the patient, which can lead to inadequate blood flow.
Visit WebsiteBoston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA) application to market the Eluvia Drug-Eluting Vascular Stent System, specifically developed for the treatment of peripheral artery disease (PAD).
Visit WebsiteAt one year following transcatheter aortic valve replacement (TAVR), implantation with the Portico valve was safe and associated with low rates of stroke, death and leaks between patients’ natural heart tissue and the Portico valve.
Visit WebsitePatients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally tolerated medical therapy demonstrated reduced rates of hospitalizations and death after being treated with the transcatheter MitraClip device. Patients in the randomized COAPT trial also showed improved quality-of-life and functional capacity.
Visit WebsiteAncora Heart Inc. announced positive clinical data from the company’s recently expanded U.S. early feasibility study evaluating the safety of the investigational AccuCinch Ventricular Repair System designed for the treatment of heart failure and functional mitral regurgitation (FMR).
Visit Website“The Cardiovascular Research Foundation (CRF) has announced the 15 late-breaking trials and 12 late-breaking clinical science presentations that will be reported at the 2018 Transcatheter Cardiovascular Therapeutics (TCT)scientific symposium.”
Visit Website“A discussion with William O’Neill, M.D., director of the structural heart program, Henry Ford Hospital, and Michele Voeltz, M.D., fellowship program director, interventional cardiology, explain their process for selecting various levels of hemodynamic support.”
Visit Website“W. L. Gore & Associates Inc. (Gore) announced the acquisition of Pipeline Medical Technologies Inc., a privately held medical technology company focused on advancing chordal repair for degenerative mitral regurgitation (DMR) via a transcatheter procedure.”
Visit Website